Floyd Petersen exercised and sold 16,679 shares of Amphastar in November, pocketing more than $441,000. He still retains about $2 million worth of shares.
RANCHO CUCAMONGA, CA / ACCESS Newswire / December 15, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for teriparatide injection, USP 560 mcg/2.24mL (250 mcg/mL) single-patient-use prefilled pen. The FDA determined that Amphastar's teriparatide is bioequivalent and therapeutically equivalent to Eli Lilly's FORTEO®.
Capital Fund Management S.A. acquired a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 40,570 shares of the company's stock, valued at approximately $931,000. Capital Fund Management S.A. owned approximately 0.09% of Amphastar Pharmaceuticals
RANCHO CUCAMONGA, CA / ACCESS Newswire / November 24, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be participating in an Analyst-Moderated fireside chat at the 37th Annual Piper Sandler Healthcare Conference on Wednesday, December 3rd, 2025, at 2:00 pm ET. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.
RANCHO CUCAMONGA, CA / ACCESS Newswire / November 12, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will be participating in an Analyst-Moderated fireside chat at the Jefferies Global Healthcare Conference on Wednesday, November 19th, 2025, at 3:30 pm GMT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com.
Amphastar Pharmaceuticals, Inc. ( AMPH ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Dan Dischner - Senior Vice President of Human Resources & Corporate Communication William Peters - CFO, Executive VP of Finance, Treasurer & Director Tony Marrs - Executive VP of Regulatory Affairs & Clinical Operations Conference Call Participants Serge Belanger - Needham & Company, LLC, Research Division Pavan Patel - BofA Securities, Research Division Ekaterina Knyazkova - JPMorgan Chase & Co, Research Division David Amsellem - Piper Sandler & Co., Research Division Benjamin Burnett - Wells Fargo Securities, LLC, Research Division Presentation Operator Greetings, and welcome to the Amphastar Pharmaceuticals, Inc. Third Quarter Earnings Call. [Operator Instructions] Please note that certain statements made during this call regarding matters that are not historical facts, including, but not limited to, management's outlook or predictions for the future periods are forward-looking statements.
The headline numbers for Amphastar (AMPH) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to earnings of $0.96 per share a year ago.
Reports Net Revenues of $191.8 million for the Three Months Ended September 30, 2025 GAAP net income of $17.4 million, or $0.37 per share, for the third quarter Adjusted non-GAAP net income of $44.7 million, or $0.93 per share, for the third quarter Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, CA / ACCESS Newswire / November 6, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company"), a biopharmaceutical company focused on developing, manufacturing, and marketing complex generic and proprietary injectable, inhalation, and intranasal products, today reported results for the three months ended September 30, 2025.
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
